European Stroke Organisation Conference 2025
May 21, 2025
Helsinki, Finland
Part of Bioxodes team will be attending the European Stroke Organisation Congress (ESOC) this year.
About
Bioxodes
Bioxodes’ innovative pipeline includes a clinical-stage program for the prevention of thrombosis and neuroinflammation in patients with an intracerebral hemorrhage (ICH).
Neuroinflammation plays a critical role in the neurologic decline of ICH patients. BIOX-101 (Ir-CPI), the lead drug candidate of this program, exhibits a unique mechanism of action by targeting coagulation factors (FXIIa & FXIa) and neutrophils, key driver components of the neuroinflammatory process. BIOX-101 prevents blood clot formation without increasing the bleeding risk — a major asset in ICH patients — due to the specific coagulation factors targeted by this compound.
In parallel, Bioxodes is developing a pipeline of drug candidates with the objectives to treat chronic thrombo-inflammatory and inflammatory diseases. The goal is to leverage the activity of BIOX-101 against neutrophil activation and neutrophil extracellular trap (NET) formation.
Our innovative pipeline includes a clinical-stage program with BIOX-101 (Ir-CPI) for the prevention of thrombosis and neuroinflammation in hemorrhagic stroke patients. Currently, our Phase IIa program is underway, aiming to gather safety data and initial evidence of efficacy in patients with ICH.
video testimonial
Prof Robin Lemmens, a world-renowned stroke expert, is the lead investigator of the current Phase 2a trial for BIOX-101 (Ir-CPI).
“Stroke is worldwide one of the main causes for mortality,” he says in this video. “We are really in need to find medication hear to try and improve their prognosis.” Professor Lemmens, the head of the stroke unit at the University Hospital Leuven (Belgium), was speaking at an investor event Bioxodes had organized in Zurich, in February 2024.
Product
All products-
![]()
BIOX-101
First-in-class clinical-stage therapeutic to treat intracerebral hemorrhage, an often lethal disease with no approved treatment.
Read more -
![]()
Pipeline
Innovative pipeline targeting multiple thrombo-inflammatory indications and with ambitious discovery program.
Read More -
![]()
Clinical trials
Launching a potentially registrational Phase 2b trial for BIOX-101. Considering a Phase 2 trial for ischemic stroke.
Read More
Advisory Board
All Key Opinion Leaders-
Read more
Robin Lemmens , M.D.
Leuven, Belgium
-
Read more
Rustam Al-Shahi Salman , MA MB BChir PhD FRCP Edin FHEA FESO
Edinburgh, United Kingdom
-
Read more
Ashkan Shoamanesh , M.D.
Hamilton, Canada
-
Read more
Matthias Endres , M.D.
Berlin, Germany
-
Read more
David Seiffge , M.D.
Bern, Switzerland
-
Read more
Cedric Hermans , M.D, Ph.D, FRCP (Lon, Edin)
Brussels, Belgium
-
Read more
Thomas Lecompte , M.D
Geneva, Switzerland
-
Read more
Denis Vivien , Ph.D
Caen, France
Recents News
BioEquity Europe
May 12, 2025
Bruges, Belgium
Our CEO Marc Dechamps will be presenting at the 25th edition of BioEquity Europe in Bruges
Can Bioxodes end the dearth of haemorrhagic stroke drugs?
April 29, 2025
Front page article in Pharmaphorum by Phil Taylor There is currently no approved treatment for intracerebral haemorrhagic (ICH) stroke, but Belgian start-up Bioxodes hopes to change that with a drug based on a protein found in the saliva of ticks.
LSX World Congress Europe
April 28, 2025
London, United Kingdom
Our CEO Marc Dechamps will be presenting in front of investors at the LSX World Congress in London.
Investors
Invest in us
Bioxodes is a Belgian private company, founded in 2013. The Company has received fundings from both the public and private investors.
